Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 30, 2020 16:15 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout

All data consistent with stronger performance of SEL-212 versus pegloticase Numerically higher response rate for SEL-212 versus pegloticase during primary endpoint of months 3 and 6 combined;...
September 24, 2020 16:17 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
September 23, 2020 07:00 ET | Source: Selecta Biosciences, Inc.

First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout

STOCKHOLM, Sweden and WATERTOWN, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the...
September 08, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
September 01, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank

WATERTOWN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
August 06, 2020 07:30 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in potential milestones, and tiered double-digit royaltiesEntered into research...
August 03, 2020 16:05 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
August 03, 2020 08:15 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
July 30, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter Financial Results and Recent Operational Highlights

WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
July 28, 2020 06:00 ET | Source: Selecta Biosciences, Inc.

Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

STOCKHOLM, Sweden and WATERTOWN, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the strategic licensing agreement with Selecta...